JDD Article Highlight
JDD’s article titled, “Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists” touches upon a significant increase in the use of GLP-1 agonists, like semaglutide and liraglutide, for weight loss has led to a rise in dermatologic adverse events, with over 6% of reported side effects being skin-related. Liraglutide was the most common culprit, followed by semaglutide and tirzepatide. The most frequent reactions were rash, pruritus, and alopecia. As these medications become more popular, it’s crucial for dermatologists to be aware of potential skin-related side effects when counseling patients.
